Answers are grounded in this paper and cite their sources.
Objective: This study aimed to evaluate the levels of testican-1 in patients diagnosed with Coronavirus Disease-2019 (COVID-19) and to investigate its potential utility in predicting disease severity and clinical progression.Testican-1, a proteoglycan with known associations with sepsis and central nervous system damage, was hypothesized to serve as a biomarker for severe cases. Materials and Methods:The study was conducted between September 15 and October 15, 2020, at University of Health Sciences Türkiye, Kayseri City Hospital, a designated pandemic center.A total of 89 patients with polymerase chain reaction-confirmed COVID-19 diagnoses were included.Patients were classified as moderate or severe based on clinical criteria.Serum testican-1 levels were measured using enzyme-linked immunosorbent assay.Routine biochemical parameters, C-reactive protein (CRP), procalcitonin, D-dimer, and other inflammatory markers, were analyzed. Results:Testican-1 levels were significantly higher in patients with severe disease and admitted to intensive care units compared to moderate cases (p<0.001).However, no statistically significant correlations were found between testican-1 levels and other clinical markers, including CRP, procalcitonin, and D-dimer.A weak positive correlation with lactate levels and, and a weak negative correlation with basophil percentages. Conclusion:Testican-1 shows promise as a specific biomarker for assessing the severity of COVID-19, potentially aiding clinicians in prognosis and management.While it does not correlate strongly with other inflammatory markers, its distinct association with severe disease underscores its utility.
No takes yet. Share an insight, caveat, or question.
Bol et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: